Reimbursement Approvals Sample Clauses

Reimbursement Approvals. The Company and each Company Entity hold all Reimbursement Approvals necessary or required by applicable Laws or Governmental Entity for the operation of the business as currently conducted by the Company and each Company Subsidiary. Section 4.8(f) of the Company Disclosure Letter sets forth all such Reimbursement Approvals held by the Company and the Company Entities as of the Closing Date or for which the Company or any Company Entity has applied (individually, a “Company Reimbursement Approval” and collectively, the “Company Reimbursement Approvals”). There are no pending or, to the knowledge of the Company, threatened suits or proceedings that have or would reasonably be expected to result in the suspension, revocation, restriction, amendment or nonrenewal of any Company Reimbursement Approvals, and to the knowledge of the Company, no event that (whether with notice or lapse of time or both) would reasonably be expected to result in a suspension, revocation, restriction, amendment or nonrenewal of any Company Reimbursement Approval has occurred. To the knowledge of the Company, each of the Company and each Company Entity is in compliance with the terms of the Company Reimbursement Approvals to which it is subject.
AutoNDA by SimpleDocs
Reimbursement Approvals. Except as could not be expected to have a Material Adverse Effect, each Company holds all Reimbursement Approvals necessary or required by applicable law or Governmental Authority for the operation of the business of such Company (individually, a “Company Reimbursement Approval,” and collectively, the “Company Reimbursement Approvals”). Reimbursement Approvals include, but are not limited to, those items listed on Schedule 3.19(a). Except as could not reasonably be expected to have a Material Adverse Effect, there are no pending or, to the knowledge of any Loan Party, threatened suits or proceedings that could reasonably be expected to result in the suspension, revocation, restriction, amendment or nonrenewal of any Company Reimbursement Approvals, and no event which (whether with notice or lapse of time or both) could reasonably be expected to result in a suspension, revocation, restriction, amendment or nonrenewal of any Company Reimbursement Approval has occurred. Except as could not reasonably be expected to have a Material Adverse Effect, each Company is in compliance with the terms of the Company Reimbursement Approvals.
Reimbursement Approvals. Except as could not be expected to have a Material Adverse Effect, each Company holds all Reimbursement Approvals necessary or required by applicable law or Governmental Authority for the operation of the business of such Company. Schedule 3.19(c) sets forth all such Reimbursement Approvals held by each Company as of the Closing Date or to be obtained by each Company within 90 days following the Closing Date (individually, a “Company Reimbursement Approval,” and collectively, the “Company Reimbursement Approvals”). There are no pending or, to the knowledge of any Loan Party, threatened suits or proceedings that could reasonably be expected to result in the suspension, revocation, restriction, amendment or nonrenewal of any Company Reimbursement Approvals, and no event which (whether with notice or lapse of time or both) could reasonably be expected to result in a suspension, revocation, restriction, amendment or nonrenewal of any Company Reimbursement Approval has occurred. Each Company is in compliance with the terms of the Company Reimbursement Approvals.
Reimbursement Approvals. KCI US and Novadaq shall work together to conduct the clinical studies and obtain all clinical data, results, information, and materials necessary for KCI US to submit to country, federal, supranational, state or local regulatory agency, department, bureau or other governmental entity that may approve or determine pricing for medical device products and procedures for reimbursement and as otherwise necessary for reimbursement of physicians and hospitals by private and public insurance or other payors for the use of a particular Product, in the countries or regulatory jurisdictions in the Territory (“Reimbursement Approval”). Novadaq shall assist KCI US in all material issues, amendments, supplements, and other matters related to the Reimbursement Approval process. KCI US shall be responsible for bearing the cost of creating and gathering the foregoing information and materials used in any Reimbursement Approval. The Parties agree to cooperate on the preparation and filing of materials to obtain Reimbursement Approvals in an efficient and expeditious manner. KCI US shall submit and maintain all filings and Reimbursement Approvals prepared pursuant to this Section 12.4.
Reimbursement Approvals. (a) The Company has Reimbursement Approval agreements with third party payors (the “Third Party Payors”). Schedule 4.17(a) sets forth a list of all Reimbursement Approvals (other than the federal health care programs set forth on Schedule 4.17(b) and the Accreditations set forth on Schedule 4.19(e)) held by the Company as of the Closing Date or to be obtained by the Company within 90 days following the Closing Date, which list includes the effective date and type of each Reimbursement Approval agreement (individually, a “Company Reimbursement Approval Contract,” and collectively, the “Company Reimbursement Approval Contracts”). Current, correct and complete copies of the Company Reimbursement Contracts have been delivered to Buyers or if such written agreements or certifications do not exist, current, correct and complete copies of other documentation evidencing such Company Reimbursement Approval Contracts have been delivered to Buyers.
Reimbursement Approvals. The Regulatory Responsible Party, itself or through its designee, will have the right to seek Reimbursement Approval and obtain the Adjusted XXX Xxxxx of the Licensed Product sold in the Field in the Territory, and the other Party will not have the right to direct, control, or approve the Adjusted XXX Xxxxx of the Licensed Product sold in the Field in the Territory. BioCryst, itself or through its designee, will have the right to seek Reimbursement Approval and to determine the price of the Licensed Product sold outside of the Territory and in the Territory outside of the Field, including all discount and rebate strategies and other economic arrangements relating to the Licensed Product outside of the Territory and in the Territory outside of the Field, and Torii will not have the right to direct, control, or approve the price of the Licensed Product sold outside of the Territory or in the Territory outside of the Field. The other Party will provide reasonably requested assistance in connection with obtaining Reimbursement Approval for the Licensed Product in the Field in the Territory, including, if required by Applicable Law, to submit any application for Reimbursement Approval or other Regulatory Submission in such Party’s name as reasonably requested by the Regulatory Responsible Party. The Regulatory Responsible Party will keep the other Party timely informed on the status of any application for Reimbursement Approval for the Licensed Product in the Field in the Territory, including any discussion with any Regulatory Authority or other Governmental Authority with respect thereto.
Reimbursement Approvals. At Lilly's sole discretion, Lilly shall make available to MiniMed, and shall authorize MiniMed to use, Confidential Information in support of MiniMed's efforts to obtain reimbursement for the Products.
AutoNDA by SimpleDocs
Reimbursement Approvals. LifeCell MR and Novadaq shall work together to conduct the clinical studies and obtain all clinical data, results, information, and materials necessary for LifeCell MR to submit to country, federal, supranational, state or local regulatory agency, department, bureau or other governmental entity that may approve or determine pricing for medical device products and procedures for reimbursement and as otherwise necessary for reimbursement of physicians and hospitals by private and public insurance or other payors for the use of a particular Product, in the countries or regulatory jurisdictions in the Territory (“Reimbursement Approval”). Novadaq shall assist LifeCell MR in all material issues, amendments, supplements, and other matters related to the Reimbursement Approval process. LifeCell MR shall be responsible for bearing the cost of creating and gathering the foregoing information and materials used in any Reimbursement Approval. The Parties agree to cooperate on the preparation and filing of materials to obtain Reimbursement Approvals in an efficient and expeditious manner. LifeCell MR shall submit and maintain all filings and Reimbursement Approvals prepared pursuant to this Section 12.4.
Reimbursement Approvals. LifeCell and Novadaq shall work together to conduct the clinical studies and obtain all clinical data, results, information, and materials necessary for LifeCell to submit to country, federal, supranational, state or local regulatory agency, department, bureau or other governmental entity that may approve or determine pricing for medical device products and procedures for reimbursement and as otherwise necessary for reimbursement of physicians and hospitals by private and public insurance or other payors for the use of a particular Product, in the countries or regulatory jurisdictions in the Territory (“Reimbursement Approval”). Novadaq shall assist LifeCell in all material issues, amendments, supplements, and other matters related to the Reimbursement Approval process. LifeCell shall be responsible for bearing the cost of creating and gathering the foregoing information and materials used in any Reimbursement Approval. The Parties agree to cooperate on the preparation and filing of materials to obtain Reimbursement Approvals in an efficient and expeditious manner. LifeCell shall submit and maintain all filings and Reimbursement Approvals prepared pursuant to this Section 12.4.

Related to Reimbursement Approvals

  • Approvals No authorization, approval or consent of any court, governmental body, regulatory agency, self-regulatory organization, or stock exchange or market or the stockholders of the Company is required to be obtained by the Company for the issuance and sale of the Securities to the Buyer as contemplated by this Agreement, except such authorizations, approvals and consents that have been obtained.

  • Project Approvals See §6.22.

  • Authorization; Approvals The issuance of the Policy and the execution, delivery and performance of this Agreement and the Insurance Agreement have been duly authorized by all necessary corporate proceedings. No further approvals or filings of any kind, including, without limitation, any further approvals of or further filings with any governmental agency or other governmental authority, or any approval of the Insurer’s board of directors or stockholders, are necessary for the Policy, this Agreement and the Insurance Agreement to constitute the legal, valid and binding obligations of the Insurer.

  • Regulatory Approvals All Requisite Regulatory Approvals shall have been obtained and shall remain in full force and effect and all statutory waiting periods in respect thereof shall have expired, and no such Requisite Regulatory Approval shall have resulted in the imposition of any Materially Burdensome Regulatory Condition.

  • Third Party Approvals (a) Subject to the terms and conditions of this Agreement, Parent and the Partnership and their respective Subsidiaries will cooperate and use their respective commercially reasonable efforts to prepare all documentation, to effect all filings, to obtain all permits, consents, approvals and authorizations of all Governmental Authorities and third parties necessary to consummate the transactions contemplated by this Agreement and to comply with the terms and conditions of such permits, consents, approvals and authorizations and to cause the Merger to be consummated as expeditiously as practicable. Each of Parent and the Partnership has the right to review in advance, and to the extent practicable each will consult with the other, in each case subject to applicable Laws relating to the exchange of information, with respect to, all material written information submitted to any third party or any Governmental Authorities in connection with the transactions contemplated by this Agreement. In exercising the foregoing right, each of the Parties agrees to act reasonably and promptly. Each Party agrees that it will consult with the Other Parties with respect to the obtaining of all material permits, consents, approvals and authorizations of all third parties and Governmental Authorities necessary or advisable to consummate the transactions contemplated by this Agreement, and each Party will keep the Other Parties apprised of the status of material matters relating to completion of the transactions contemplated hereby.

  • Consents, Licenses, Approvals, etc Lender shall have received copies of all consents, licenses and approvals, if any, required in connection with the execution, delivery and performance by Borrower, and the validity and enforceability, of the Loan Documents, and such consents, licenses and approvals shall be in full force and effect.

  • Licenses, Permits and Approvals Seller has not received any written notice, and Seller has no knowledge that the Property fails to comply with all applicable licenses, permits and approvals and federal, state or local statutes, laws, ordinances, rules, regulations, requirements and codes including, without limitation, those regarding zoning, land use, building, fire, health, safety, environmental, subdivision, water quality, sanitation controls and the Americans with Disabilities Act, and similar rules and regulations relating and/or applicable to the ownership, use and operation of the Property as it is now operated. Seller has received all licenses, permits and approvals required or needed for the lawful conduct, occupancy and operation of the business of the Hotel, and each license and permit is in full force and effect, and will be received and in full force and effect as of the Closing. No licenses, permits or approvals necessary for the lawful conduct, occupancy or operation of the business of the Hotel, to Seller’s knowledge requires any approval of a governmental authority for transfer of the Property except as set forth in Exhibit D.

  • Regulatory Approvals; No Defaults (a) No consents or approvals of, or waivers by, or filings or registrations with, any Governmental Authority are required to be made or obtained by HCBF or any of its Subsidiaries in connection with the execution, delivery or performance by HCBF of this Agreement or to consummate the transactions contemplated by this Agreement, except as may be required for (i) filings of applications and notices with, and receipt of consents, authorizations, approvals, exemptions or nonobjections from, the SEC, NASDAQ, state securities authorities, the Financial Industry Regulatory Authority, Inc., applicable securities, commodities and futures exchanges, and other industry self-regulatory organizations (each, an “SRO”), (ii) filings of applications or notices with, and consents, approvals or waivers by the FRB, the FDIC and applicable state banking agencies, the Office of the Comptroller of the Currency (the “OCC”), the Florida Office of Financial Regulation (the “FOFR”) and other banking, regulatory, self-regulatory or enforcement authorities or any courts, administrative agencies or commissions or other Governmental Authorities and approval of or non-objection to such applications, filings and notices (taken together with the items listed in clause (i), the “Regulatory Approvals”), (iii) the filing with the SEC of the Proxy Statement-Prospectus and the Registration Statement and declaration of effectiveness of the Registration Statement, (iv) the filing of the Articles of Merger and the filing of documents with the OCC, applicable Governmental Authorities, and the Secretary of State of the State of Florida to cause the Bank Merger to become effective and (v) such filings and approvals as are required to be made or obtained under the securities or “Blue Sky” laws of various states in connection with the issuance of the shares of CenterState Common Stock pursuant to this Agreement and approval of listing of such CenterState Common Stock on the NASDAQ. Subject to the receipt of the approvals referred to in the preceding sentence and the Requisite HCBF Shareholder Approval, the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby by HCBF do not and will not (1) constitute a breach or violation of, or a default under, the articles of incorporation, bylaws or similar governing documents of HCBF or any of its respective Subsidiaries, (2) violate any statute, code, ordinance, rule, regulation, judgment, order, writ, decree or injunction applicable to HCBF or any of its Subsidiaries, or any of their respective properties or assets, (3) conflict with, result in a breach or violation of any provision of, or the loss of any benefit under, or a default (or an event which, with or without notice or lapse of time, or both, would constitute a default) under, result in the creation of any Lien under, result in a right of termination or the acceleration of any right or obligation under any permit, license, credit agreement, indenture, loan, note, bond, mortgage, reciprocal easement agreement, lease, instrument, concession, contract, franchise, agreement or other instrument or obligation of HCBF or any of its Subsidiaries or to which HCBF or any of its Subsidiaries, or their respective properties or assets is subject or bound, or (4) require the consent or approval of any third party or Governmental Authority under any such Law, rule or regulation or any judgment, decree, order, permit, license, credit agreement, indenture, loan, note, bond, mortgage, reciprocal easement agreement, lease, instrument, concession, contract, franchise, agreement or other instrument or obligation.

  • Licenses Awarded Vendor shall maintain, in current status, all federal, state and local licenses, bonds and permits required for the operation of the business conducted by awarded Vendor. Awarded Vendor shall remain reasonably fully informed of and in compliance with all ordinances and regulations pertaining to the lawful provision of goods or services under the Agreement. TIPS and TIPS Members reserves the right to stop work and/or cancel an order or terminate this or any other sales Agreement of any awarded Vendor whose license(s) required for performance under this Agreement have expired, lapsed, are suspended or terminated subject to a 30-day cure period unless prohibited by applicable statue or regulation.

  • Agency Approvals The Servicer is an approved servicer for FHLMC, FNMA, GNMA, HUD and VA is an FHA-Approved Mortgagee and is qualified to own and hold VA Mortgage Loans, and shall maintain such approvals throughout the term of this Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.